
Opinion|Videos|August 29, 2024
Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting
Key opinion leaders address the availability of brexucabtagene autoleucel (brexu-cel) at their institutions and outline procedures for ensuring risk evaluation and mitigation strategy compliance and comprehensive training across multidisciplinary teams.
Advertisement
Video content above is prompted by the following:
- For those who have brexu-cel on-formulary or available at your institution, what processes did you and your team take to ensure REMS compliance and training among multidisciplinary team members?
- Typically, is a physician, pharmacist, nurse, quality coordinator or another member of the team the REMS Authorized Representative?
- At your institution, are patients receiving CAR-T cell Therapy in the outpatient or inpatient setting?
- For those infusing CAR-T cell Therapy in the outpatient setting, how are patients being monitored?
Advertisement
Related to this article

Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
The OncFive: Top Oncology Articles for the Week of 10/4/2026
5



